Additional analysis of gene polymolphisms in the phase II study of erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitis (UMIN000007020)
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000012622
- Lead Sponsor
- ung Oncology Group in Kyushu, Japan (LOGIK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
Nothing particular
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gene polymorphisms analysis
- Secondary Outcome Measures
Name Time Method